Bitterwood (Picrasma excelsa)

Bitterwood (Picrasma excelsa) is a Caribbean tree containing quassinoids, bitter compounds traditionally used in Jamaican folk medicine for blood sugar management. These quassinoids may influence glucose metabolism and enzyme activity, though clinical evidence remains limited.

Origin & History

Bitterwood (Picrasma excelsa) is a tree native to the Caribbean, particularly Jamaica, belonging to the Simaroubaceae family. The medicinal wood from the trunk and branches is extracted via infusion, decoction, or alcohol to yield bitter compounds called quassinoids, including quassin and neoquassin, with typical commercial yields of 0.1-0.2%.

Historical & Cultural Context

In Jamaican folk medicine, Picrasma excelsa wood infusions, known as Jamaican bitterwood tea, are traditionally consumed to lower blood sugar in diabetics, often alongside prescription medications. The wood's intense bitterness has been historically valued as a tonic and digestif, similar to related Quassia species.

Health Benefits

• Blood sugar management - traditionally used in Jamaican folk medicine for diabetes (traditional evidence only)
• Digestive tonic - historically used for digestive support due to bitter principles (traditional evidence only)
• Potential drug metabolism effects - inhibits CYP1A1 enzyme in vitro (IC50 9.2-11.9 μM) (preliminary in vitro evidence)
• No clinical trial evidence available for any health benefits
• Limited to traditional use reports without human studies

How It Works

Bitterwood's quassinoid compounds, particularly quassin and neoquassin, exert biological effects through bitter taste receptor activation and enzyme inhibition. The extract demonstrates CYP1A1 enzyme inhibition in vitro, potentially affecting drug metabolism pathways. These quassinoids may also influence glucose metabolism through unknown mechanisms in traditional diabetes management.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified for Picrasma excelsa. The only scientific study found was an in vitro investigation (PMID: 19016402) examining CYP1A1 enzyme inhibition by quassin and neoquassin, reporting IC50 values of 9.2 μM and 11.9 μM respectively, which focused on drug metabolism interactions rather than therapeutic outcomes.

Clinical Summary

Current evidence for bitterwood is limited to traditional use documentation and in vitro studies. Laboratory research shows CYP1A1 enzyme inhibition with an IC50 value, but specific concentrations and clinical relevance remain unclear. No randomized controlled trials have evaluated bitterwood's effects on blood sugar management or digestive health in humans. Traditional evidence from Jamaican folk medicine provides historical context but lacks quantified clinical outcomes.

Nutritional Profile

Bitterwood (Picrasma excelsa) is a medicinal bark/wood preparation with negligible macronutrient content in typical therapeutic doses. Primary bioactive compounds are quassinoids (bitter principles), which are the defining phytochemical class: nigakilactone derivatives, picrasin A-F (particularly picrasin B as a dominant quassinoid), and beta-carboline alkaloids including 4-methoxy-1-vinyl-beta-carboline and canthin-6-one alkaloids. Quassinoid concentration in dried bark is estimated at 0.1-0.5% dry weight based on related Picrasma/Quassia species data. Canthin-6-one alkaloids present at trace levels (<0.1% dry weight). Also contains beta-sitosterol and campesterol (phytosterols), tannins (condensed and hydrolysable, estimated 2-5% dry weight), and flavonoid glycosides at low concentrations. No clinically meaningful vitamins or minerals are contributed in standard decoction doses. Fiber content is structurally present in bark preparations but not bioavailable in typical aqueous extracts. Bioavailability of quassinoids from decoctions is not formally characterized; lipophilic quassinoids likely have moderate oral bioavailability based on structural analogs. The CYP1A1 inhibitory activity (IC50 9.2-11.9 μM in vitro) is attributed to the alkaloid and quassinoid fractions collectively, though specific responsible compounds are not yet isolated with certainty.

Preparation & Dosage

No clinically studied dosage ranges have been established for Picrasma excelsa in any form (extracts, powder, or standardized preparations). Traditional use involves wood infusions prepared as tea, but specific amounts are not documented in available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Gymnema sylvestre, Cinnamon bark, Bitter melon, Chromium picolinate

Safety & Interactions

Bitterwood safety profile in humans has not been established through clinical trials. The documented CYP1A1 enzyme inhibition suggests potential drug interactions, particularly with medications metabolized by this pathway. Quassinoids can cause gastrointestinal irritation in sensitive individuals due to their intense bitter properties. Pregnancy and breastfeeding safety data is unavailable, warranting avoidance during these periods.